AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23772853
Drug: Perampanel 2-12
RxNorm normalized name: perampanel 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 2-12 mg
Trial: 20439606
Drug: Dual-boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-boosted protease inhibitor combinations
Trial: 10596413
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose treatment with surfactant (Curosurf)
Trial: 10596413
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose treatment with surfactant (Curosurf)
Trial: 6962738
Drug: Cigarette averaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette averaging .64 mg nicotine (P2)
Trial: 6962738
Drug: Cigarette averaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette averaging .38 mg nicotine (P3)
Trial: 6962738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group switched to another brand within ± .1 mg of their usual brand (P2)
Trial: 6962738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group switched to another brand within ± .1 mg of their usual brand (P3)
Trial: 27404053
Drug: MPFF 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 500 mg
Trial: 28804864
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS)
Trial: 24012456
Drug: < 3
RxNorm normalized name: Ryoncil Kit Patient Weight 25 - < 37.5 KG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: < 3 CTC per 7.5 mL blood and KRAS wild-type tumors
Trial: 21345850
Drug: More intense
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intense therapy (low-dose hydrochlorothiazide and low-dose felodipine)
Trial: 21345850
Drug: Less-intense therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intense therapy (low-dose hydrochlorothiazide and placebo)
Trial: 10211032
Drug: Ropivacaine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 75 mg in 0.9% saline 60 ml
Trial: 25827960
Drug: 10mg/m(2)/day of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/m(2)/day of oral hydrocortisone in three divided doses
Trial: 24640651
Drug: Coordination gymnastics
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordination gymnastics combined with magnetic therapy and iodine-bromine baths
Trial: 16322489
Drug: Trials with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials with a treatment window >6 hours
Trial: 16322489
Drug: Trials with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials with a treatment window <=6 hours
Trial: 14613518
Drug: Omacor 1
RxNorm normalized name: Omacor 1 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor 1 g, o.d.
Trial: 8822290
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CAE) for 5 days at 30 mg/kg/day in 2 divided doses
Trial: 8822290
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CAE) for 10 days at 30 mg/kg/day in 2 divided doses
Trial: 8822290
Drug: Amoxicillin/clavulanate (AMX/CL)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (AMX/CL) for 10 days at 40 mg/kg/day in 3 divided doses
Trial: 6523650
Drug: Cefuroxime (antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (antibiotic group)
Trial: 22508376
Drug: Carbidopa 75
RxNorm normalized name: carbidopa 18.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa 75 mg/day
Trial: 2163805
Drug: BAY m1099
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY m1099 (50 mg thrice daily)
Trial: 2024740
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 10 mg
Trial: 22395731
Drug: Dopamine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine antagonist (haloperidol)
Trial: 9141982
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid (fluticasone) 200 micrograms when needed (up to 400 micrograms/d) + 1-2 tablets of terfenadine daily (max 120 mg/d)
Trial: 9141982
Drug: Antihistamine (terfenadine)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (terfenadine) 1 tablet of 60 mg when needed (max 120 mg/d) + 200-400 micrograms/d of fluticasone nasal spray if needed
Trial: 3099611
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium nasal spray for 6 weeks together with terfenadine for 1 week
Trial: 28592016
Drug: Oseltamivir (30‐75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (30‐75 mg, twice daily for 5 days)
Trial: 18182196
Drug: Infusion pump
RxNorm normalized name: Infusion Pump 50cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion pump with 0.5% bupivacaine
Trial: 18182196
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block combined with an infusion pump containing 0.9% saline solution
Trial: 18182196
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block combined with an infusion pump containing 0.5% bupivacaine
Trial: 18182196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Infusion pump with saline solution)
Trial: 10589439
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata dried extract (1200 mg/day)
Trial: 8636343
Drug: Fludrocortisone 0.1
RxNorm normalized name: fludrocortisone 0.1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 0.1 mg
Trial: 8636343
Drug: Fludrocortisone 0
RxNorm normalized name: fludrocortisone 0.001 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 0 mg (placebo)
Trial: 6168840
Drug: Pindolol (10‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10‐45 mg/day)
Trial: 31033396
Drug: Ad exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad exposure frequency (viewing the ad once, twice, or four times)
Trial: 19180894
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied to one-half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Trial: 19180894
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied to the other half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Trial: 13680283
Drug: 3x2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x2 mg budesonide
Trial: 13680283
Drug: 3x6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x6 mg budesonide
Trial: 11679989
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, and 1 x 10(6) KIU before reperfusion; n = 10)
Trial: 11679989
Drug: Regular-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular-dose aprotinin (2 x 10(6) KIU at induction and continuous infusion of 0.5 x 10(6) KIU/h; n = 8)
Trial: 8003847
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (n = 939)
Trial: 8003847
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (n = 939) among women who had never used oestrogen replacement therapy (n = 1427)
Trial: 8003847
Drug: Non-users (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users (n = 2283) among women who had never used oestrogen replacement therapy (n = 1427)
Trial: 8003847
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (n = 939) among premenopausal women (n = 387)
Trial: 3341390
Drug: Indapamide 1
RxNorm normalized name: indapamide 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1 mg per day
Trial: 3341390
Drug: Indapamide 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 5.0 mg per day
Trial: 17184605
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk containing Lactobacillus casei and Streptococcus thermophilus (0.5 l/day) for 6 weeks
Trial: 17184605
Drug: Standard cow's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cow's milk (0.5 l/day) for 12 weeks
Trial: 15004973
Drug: Zi-Factor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zi-Factor (250 mg azithromycin capsules)
Trial: 15004973
Drug: Reference-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference-drug
Trial: 6377153
Drug: Single 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-g oral dose of metronidazole (Flagyl)
Trial: 11257348
Drug: DTPa-HBV-IPV/Hib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-HBV-IPV/Hib combination vaccine
Trial: 18611978
Drug: Transdermal E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal E(2) supplementation
Trial: 16488678
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration 4 hours postoperatively, daily for 4 weeks
Trial: 16488678
Drug: No clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No clopidogrel administration
Trial: 26903002
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration
Trial: 11023194
Drug: Intratumoral interferon-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral interferon-gamma (IFN-gamma) retroviral vector, 10(7) plaque-forming units/mL administered at 0.3, 0.5, and 1.0 mL per cohort of patients, five daily injections every 2 weeks.
Trial: 11023194
Drug: Intratumoral interferon-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral interferon-gamma (IFN-gamma) retroviral vector, multiple injections.
Trial: 9376465
Drug: Metamizol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol (1 g/100 ml NaCl 0.9% intravenously over 15 min) plus diclofenac (100 mg suppository) administered before induction and repeated at 6 h and 12 h.
Trial: 29580238
Drug: Traditional facility-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional facility-based treatment for SAM
Trial: 12468439
Drug: High-dose fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluticasone propionate (500 microg twice a day)
Trial: 12468439
Drug: Low-dose fluticasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluticasone propionate (100 microg twice a day)
Trial: 8750370
Drug: Intravenous TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TCA (2 mg as phosphate ester)
Trial: 8750370
Drug: Oral TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TCA (5 mg)
Trial: 8750370
Drug: Inhaled TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TCA (2 mg)
Trial: 7408529
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mefenamic acid three times daily
Trial: 31987558
Drug: No stretch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stretch, 30 s stretch, multiple (4×) 30 s stretch, and dynamic stretch (treatment conditions)
Trial: 17580512
Drug: Orthotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthotropic treatment (growth guidance)
Trial: 15767953
Drug: Morphine aerosols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine aerosols (4 mls of morphine sulphate nebulised 4 hourly)
Trial: 15767953
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline aerosols (4 mls of normal saline nebulised 4 hourly)
Trial: 30348586
Drug: teriflunomide 14
RxNorm normalized name: teriflunomide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: teriflunomide 14 mg
Trial: 22768848
Drug: Discharge planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discharge planning therapies primarily within the home environment
Trial: 29097974
Drug: Information processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information processing strategy training (PRPP System of Intervention and 4QM), 50 minutes per session, twice a week for 6 weeks
Trial: 29097974
Drug: Traditional intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional intervention, twice a week for 6 weeks
Trial: 24330156
Drug: NF3 (two-herb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NF3 (two-herb traditional Chinese medicine)
Trial: 19226381
Drug: Entecavir 1.0
RxNorm normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1.0 mg/day for 52 weeks
Trial: 19226381
Drug: Entecavir 1.0
RxNorm normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1.0 mg/day for additional 68-92 weeks
Trial: 19226381
Drug: Entecavir treatment
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir treatment with annual liver biopsies
Trial: 11726010
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with diuretics or beta-blockers (Group 1)
Trial: 11726010
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with calcium channel blockers or angiotensin-converting enzyme inhibitors (Group 2)
Trial: 9164833
Drug: SCT+Ca (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT+Ca (100 IU/day I.M. of SCT plus 1200 mg of elemental Ca for 10 days each month)
Trial: 9164833
Drug: Ca (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca (1200 mg of elemental Ca for 10 days each month)
Trial: 3609189
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (2 X 4 mg)
Trial: 3609189
Drug: Subcutaneous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adrenaline (2 X 0.5 mg)
Trial: 25722360
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) for 6 weeks, weekly sessions.
Trial: 20516379
Drug: cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilostazol (100 to 200 mg/d)
Trial: 20516379
Drug: aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (81 to 100 mg/d)
Trial: 19264451
Drug: Levetiracetam XR
RxNorm normalized name: levetiracetam Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam XR with food (1000mg single dose)
Trial: 15723428
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of nizatidine 300 mg capsules
Trial: 15723428
Drug: Innovator formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator formulation of nizatidine 300 mg capsules
Trial: 3197710
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both formulations
Trial: 23672224
Drug: Western drugs
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western drugs
Trial: 1752926
Drug: Spontaneous urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous urinary luteinizing hormone (LH) surge
Trial: 7133974
Drug: Pirprofen 200
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirprofen 200 mg
Trial: 11180025
Drug: Mizolastine 5
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 5 mg
Trial: 11180025
Drug: Mizolastine 15
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 15 mg
Trial: 7875184
Drug: Mizolastine 45
RxNorm normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 45 mg
Trial: 28809990
Drug: Desoximetasone 0.05%
RxNorm normalized name: DESOXIMETASONE 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone 0.05% spray
Trial: 28809990
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator control (clobetasol spray)
Trial: 12490789
Drug: Full-dose CsA
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose CsA (microemulsion) plus fixed-dose SRL (2 mg/day; group A, n=97)
Trial: 9661093
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral electroconvulsive therapy (ECT)
Trial: 3745846
Drug: metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 10 mg q.i.d.
Trial: 18207124
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin + topical prednisolone phosphate
Trial: 18207124
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin + placebo
Trial: 15381937
Drug: 5-Fluorouracil 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil 500 mg/m² plus Epirubicin 75 mg/m² and Cyclophosphamide 500 mg/m² (FEC)
Trial: 11416804
Drug: Kinestherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinestherapy and inhaled bronchodilator drugs (salbutamol and/or ipratropium bromide) with a boreal nebulizer, bronchial hygiene, breathing exercises on a Bodyguard Ergometer 990, treated three times per week for twelve weeks.
Trial: 3790399
Drug: Ethanol consumption
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol consumption (66 g per day)
Trial: 26653612
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR 60 mg once daily (FIRST group)
Trial: 26653612
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR 60 mg once daily (SWITCH group)
Trial: 26653612
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR 60 mg once daily
Trial: 25439972
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT), 8 sessions of 2 hours each
Trial: 2898244
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) (2 mg/day)
Trial: 2898244
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GST) (50 mg/week)
Trial: 29659969
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg aspartame/d
Trial: 29659969
Drug: 1050 mg
RxNorm normalized name: guaifenesin 1050 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1050 mg aspartame/d
Trial: 29659969
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg aspartame/d (control group)
Trial: 26148063
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis before skin incision
Trial: 26148063
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis after umbilical cord clamping
Trial: 21154195
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (83 μg or 3,332 IU daily for 1 year)